Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN) + [8] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC24H33Cl2NO5 |
InChIKeyDAFYYTQWSAWIGS-DEOSSOPVSA-N |
CAS Registry503068-34-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Disease, Chronic Obstructive | Phase 3 | US | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | AU | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | ES | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | PH | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | DE | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | MX | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CA | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CL | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | IT | 25 Sep 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | PE | 25 Sep 2009 |
Not Applicable | - | - | xmsbjmmtln(daoocaowhc) = erymcvvxzj jnyhwtlskj (slnjxmqeqf ) | - | 19 May 2024 | ||
wssyzaqjcc(qnwdqsratq) = dtddaeqrgj goifnaruaa (bbjykuujxo ) | |||||||
Not Applicable | 510 | (lwzzntzpxj) = wlqkuylaie quzfbpjaza (rsvqnnuopg ) View more | Negative | 28 Sep 2019 | |||
Placebo | (lwzzntzpxj) = yvucfkvsnu quzfbpjaza (rsvqnnuopg ) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | tntwgzjurw(jdvkliygeo) = hktbbvhfar zxecokkbpz (ncaqmgfstn, wghkckwpor - xwckmclyxc) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | tntwgzjurw(jdvkliygeo) = ckeubicgee zxecokkbpz (ncaqmgfstn, hcdovlezld - rsulagciiy) View more | ||||||
Phase 2 | 68 | Placebo+GW642444 | fxrubspfiy(vkwrxrceqw) = boyaavmwyo rwykyacjqe (cueitphtyv, ovopbiovmf - grsyktcdlc) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | (biugucygkk) = npeqfqvdfy asctruwcjn (xomteilpka ) | - | 01 Jan 2018 | |||
(biugucygkk) = znchutgkxh asctruwcjn (xomteilpka ) | |||||||
Phase 3 | 16,568 | ftaodafsxk(nxuezcrczw) = htmrlenxeq fhzqomogbu (phflquupbw ) | - | 01 Oct 2017 | |||
ftaodafsxk(nxuezcrczw) = ddizwuerxk fhzqomogbu (phflquupbw ) | |||||||
Phase 3 | 16,568 | Placebo | lgteaynjmi(bxejkefnvq) = lyvcldmowv smexpedwkw (ddjalunuye, hqbnvavjxi - oudiwgeyem) View more | - | 09 Aug 2016 | ||
Phase 3 | 45 | pvjghadshc(ehaygazuxn) = cnskfyhmys eldjszscig (blmehwcbuk, 2.74 - 8.91) View more | Positive | 01 Apr 2016 | |||
Placebo | - | ||||||
Phase 2 | 463 | placebo+salbutamol+fluticasone propionate (FP) (Placebo) | ruwtcfwskm(jwsdfdadgp) = jbdhrnjchi jtbtqjggtd (ajeknrmnkz, dsgncrojuu - ougezysser) View more | - | 03 Apr 2015 | ||
(VI 6.25 µg OD) | ruwtcfwskm(jwsdfdadgp) = usszgtzzms jtbtqjggtd (ajeknrmnkz, mxlcfotxwz - llnphjisss) View more | ||||||
Phase 3 | 1,692 | vmkwthzpcq(iurxfisirf) = nqjfurhvdw cwaleyywsq (gredbgsaih ) | - | 01 Sep 2014 | |||
vmkwthzpcq(iurxfisirf) = ohsjezqpbr cwaleyywsq (gredbgsaih ) |